In a clinical trial involving ESCC patients undergoing tislelizumab plus chemotherapy followed by esophagectomy, levels of CD8+ T cells, Ths, Tregs, and mature DCs were significantly increased in pathological complete response (pCR) group, while the density of B cells and neutrophils significantly decreased (76). Here, CD8A is linked to esophageal squamous cell carcinoma.